Although field change in DNA methylation or loss of chromosome 9 heterogeneity may initiate bladder tumorigenesis, our study for the first time demonstrated an association between TERT promoter mutations and field change and also showed their clinical utility as prognostic biomarkers for bladder cancer recurrence. This evidence concerns the gene TERT and urinary bladder cancer.